Dizal Pharmaceutical (688192.SH): Multiple research results on hematology oncology products selected for the 68th American Society of Hematology (ASH) Annual Meeting

Dizal Pharmaceutical (688192.SH) announced that at the 68th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, USA, from December 12 to 15, the company will present 8 latest clinical research results from its hematology oncology pipeline, including 3 oral presentations and 5 poster presentations, covering its three core products in the hematology oncology fieldthe highly selective JAK1 inhibitor Gaoruzhe (golidocitinib), the LYN/BTK dual-target inhibitor birelentinib, and the next-generation EZH1/2 dual-target small molecule inhibitor GW5282. Among them, Gaoruzhe and birelentinib received oral presentations, and the clinical research data of GW5282 for relapsed/refractory non-Hodgkin lymphoma (r/r NHL) will also be disclosed for the first time. It is reported that Gaoruzhe is the world's first and currently the only approved highly selective JAK1 inhibitor for peripheral T-cell lymphoma (PTCL). In exploratory studies across multiple T-cell lymphoma subtypes and certain hematologic immune diseases, the drug has shown encouraging preliminary efficacy. At this congress, a total of 5 latest clinical research updates on Gaoruzhe were selected.